Ignite Creation Date:
2024-05-06 @ 3:16 PM
Last Modification Date:
2024-10-26 @ 1:46 PM
Study NCT ID:
NCT04570527
Status:
UNKNOWN
Last Update Posted:
2020-09-30
First Post:
2020-09-25
Brief Title:
Optimized Cardioprotection Therapy in Obese Subjects With CAD
Sponsor:
Xijing Hospital
Organization:
Xijing Hospital
Study Overview
Official Title:
Effects and Mechanism of Adipokines Cardiac Protection in Obese Patients With Coronary Artery Disease CAD
Status:
UNKNOWN
Status Verified Date:
2020-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the efficacy and mechanism of Adipokines Cardiac Protection in Obese Patients With coronary artery disease CAD
Detailed Description:
Adipokines or adipocytokines can be defined as a group of more than 600 bioactive molecules made from adipose tissue that acts as paracrine and endocrine hormones Adipokines are involved in maintaining varieties of processes such as appetite and satiety energy expenditure activity endothelial function blood pressure hemostasis adipogenesis insulin sensitivity energy metabolism in insulin-sensitive tissues fat distribution and insulin secretion in pancreatic β-cells Adipokines may contribute to reduce scar formation and improve cardiac function in coronary artery disease CAD Reperfusion therapy such as percutaneous coronary intervention PCI should be administered to all eligible patients with CAD symptom However our previous work showed that obese patients may benefit more from PCI Thus the aim of the present study was to investigate the efficacy and mechanism of adipokines cardiac protection for obese and non-obese patients with coronary artery disease CAD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None